Maria Zalath

Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers

Chien‐Hsing Chang, Yang Wang, Maria Zalath et al. · Molecular Cancer Therapeutics · 2016 · 56 citations

Medicine, Oncology, Pharmacology +15

Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines

Rhona Stein, Mitchell R. Smith, Susan Chen et al. · Clinical Cancer Research · 2009 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer

Thomas M. Cardillo, Diane L. Rossi, Maria Zalath et al. · Oncotarget · 2020 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

Thomas M. Cardillo, Serengulam V. Govindan, Maria Zalath et al. · Molecular Cancer Therapeutics · 2017 · 24 citations

Medicine, Oncology, Pharmacology +17

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas

Thomas M. Cardillo, Maria Zalath, Roberto Arrojo et al. · Oncotarget · 2024 · 13 citations · Full text

Medicine, Oncology, Pharmacology +9